Lv3
380 积分 2024-09-01 加入
Letter re: Ki-67 index after neoadjuvant endocrine therapy as a prognostic biomarker in patients with ER-positive/HER2-negative early breast cancer: A systematic review and meta-analysis
26天前
已关闭
Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors – An analysis of 2765 patients from neoadjuvant clinical trials
26天前
已完结
Neoadjuvant chemotherapy combined with endocrine therapy for hormone receptor-positive breast cancer: A systematic review and meta-analysis
26天前
已完结
Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer
26天前
已完结
Neoadjuvant therapy for ER-positive breast cancers
26天前
已关闭
Radiological, pathological and surgical outcomes after neoadjuvant endocrine treatment in patients with ER-positive/HER2-negative breast cancer with a clinical high risk and a low-risk 70-gene signature
26天前
已完结
The Immune Microenvironment in Hormone Receptor–Positive Breast Cancer Before and After Preoperative Chemotherapy
26天前
已完结
Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopausal patients in PENELOPE-B
26天前
已完结
The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial
26天前
已关闭
Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives
26天前
已完结
皖公网安备34019202002308
